Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Sharmila Joshi, Head of Equity, Peerless Securities is of the view that one can switch to Cipla from Ranbaxy Laboratories.
Jagannadham Thununguntla, Strategist & Head of Research at SMC Global Securities Limited is of the view that short term trader can book profits in Cipla but with a medium to long term view one can hold it.
According to Parag Doctor, Head - Trading Strategies at Keynote Capital's Ltd, one can book partial profits in Cipla around Rs 450. It has been a laggard as compared to the other pharma stocks in the Nifty and it is pretty much now in an uptrend and trying to get to similar levels, which have been seen by the other stocks.
One can sell Cipla, says Sudarshan Sukhani of s2analytics.com.
On CNBC-TV18's show Super Six, market gurus Vishal Kshatriya of Edelweiss, Rakesh Gandhi of FRR Shares and Shardul Kulkarni of Angel Broking, place their bets on two stocks each, thus offering investors a variety of options to choose from. Investors can read into the detailed analysis before agreeing to any or all the bets.
On CNBC-TV18's show Super Six, market gurus Rajesh Jain, Religare Securities, Vikrant Jadeja, vibranttrades.com and Vishal Malkan, malkansview.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.
Rajesh Agarwal, Head of Research, Eastern Financiers is of the view that Cipla, ICICI Bank and ITC seems to be a good buy for a longer term horizon.
Jitendra Panda, Capital First Securities is of the view that Cipla has target of Rs 416.
On CNBC-TV18's show Super Six, market gurus Shardul Kulkarni Angel Broking, Rajeev Agarwal, dynamixresearch.in and Vikrant Jadeja, Vibrant Trades share, place their bets on two stocks each, thus offering investors a variety of options to choose from.
One can buy Cipla , says Sudarshan Sukhani of s2analytics.com.
On CNBC-TV18's show Super Six, market gurus Shardul Kulkarni Angel Broking, Rajeev Agarwal, dynamixresearch.in and Vikrant Jadeja, Vibrant Trades share, place their bets on two stocks each, thus offering investors a variety of options to choose from.
Sudarshan Sukhani of s2analytics.com is of the opinion that one can buy Cipla.
SP Tulsian, sptulsian.com is of the view that one should hold Cipla Rs 410.
Sudarshan Sukhani, s2analytics.com advises to switch from Shasun Pharmaceuticals to Dr Reddy and Cipla.
Sudarshan Sukhani, s2analytics.com is upbeat on Cipla and Dr Reddys Labs.
Jitendra Panda of Capital First Securities feels that one can buy Cipla with a target of Rs 396.
Chirag Talati, Pharma Analyst at Espirito Santo Securities is bullish on Cipla.
On CNBC-TV18's show Super Six, market gurus Vishal Malkan, malkansview.com, Vishal Kshatriya, Edelweiss and Vikrant Jadeja, vibranttrades.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.
Sudarshan Sukhani of s2analytics.com advises trader to buy Cipla, Ranbaxy and HUL on dips.
One should go long in Cipla and it can test Rs 410-415, says Sudarshan Sukhani of s2analytics.com.
On CNBC-TV18's show Super Six, market gurus Rajesh Jain, Religare Sec, Manas Jaiswal, manasjaiswal.com and Shardul Kulkarni, Angel Broking, place their bets on two stocks each, thus offering investors a variety of options to choose from.
Buy Cipla, says Sudarshan Sukhani of s2analytics.com.
Buying opportunity is seen in Cipla, HPCL and BPCL, says Sudarshan Sukhani, s2analytics.com.
In an interview to CNBC-TV18, VK Sharma of HDFC Securities shared his reading and outlook on Futures and Options market and specific stocks.
VK Sharma of HDFC Securities advised buying Cipla 380 call at around Rs 8 with a stop loss at Rs 5.